GenuCure, Inc. 

GenuCure is turning back the clock on aging

OWNER

Ilir Dubova (See Profile)

Sector

Biotech

Stage

Prototyping, preclinical

Country

USA & Spain


TGA platform is used for developing therapeutics without limits for all tissues that have gone through aging process

No modifications made in DNA, so it is much safer than conventional gene therapy which may cause mutations in genome

Multiple genes/tissues are targeted in one application, compared to single gene approach in conventional gene therapy

TGA platform avoids off-target effects that gene editing may cause, therefore a much safer option

GenuCure has a very strong IP protection with Exclusive Option Agreement

This information is confidential, do not share or copy.

Under evaluation at least till: 9th December

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2021 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar